The Public Company Accounting Oversight Board announced on Monday that it had
issued orders instituting disciplinary proceedings against Deloitte & Touche
LLP and a former Deloitte audit partner, James L. Fazio, CPA, for violations of
the Board’s interim auditing standards in connection with the firm’s
2003 audit for Ligand Pharmaceuticals Incorporated.
Without admitting or denying the Board’s findings, Deloitte consented
to an order imposing a $1 million civil money penalty. As described in the order,
Deloitte has implemented changes to its quality control policies and procedures
for identifying and addressing potential audit quality concerns regarding the
performance and deployment of its audit partners.
The order required Deloitte to undertake certain documentation practices relating
to these additional quality control policies and procedures. The firm was also
censured.
Mr. Fazio consented to an Order barring him from being an associated person
of a public accounting firm that is registered with the PCAOB. After two years
from the date of the order, Mr. Fazio may file a petition for Board consent
to associate with a registered public accounting firm.
“Our enforcement program is vital for assuring that public confidence
is not undermined by firms or individual audit professionals who fail to meet
the profession’s high standards of quality and competence,” explained
Mark W. Olson, PCAOB Chairman.
“The Board’s orders against Deloitte and Mr. Fazio are important
examples of holding the audit profession accountable to those standards to protect
the investing public. I commend the Board’s enforcement staff for the
rigor and diligence it brought to this complex case,” he added.
In its order, the Board found that Deloitte assigned Mr. Fazio to serve as
the engagement partner for its audit of Ligand’s 2003 financial statements.
The Board also found that Deloitte assessed the engagement risk of the 2003
audit as greater than normal.
According to PCAOB findings, during the audit, Mr. Fazio failed to perform
appropriate and adequate audit procedures related to Ligand’s reported
revenue from sales of products for which a right of return existed, and failed
to supervise others adequately to ensure the performance of such procedures.
Mr. Fazio neither performed nor ensured the performance of procedures that
adequately took into account the existence of factors indicating that Ligand’s
ability to make reasonable estimates of product returns may have been impaired.
Moreover, in evaluating the reasonableness of Ligand’s estimates of future
returns, the PCAOB continued, Mr. Fazio neither performed nor ensured the performance
of procedures that adequately took into account the extent to which Ligand had
consistently and substantially underestimated its product returns. In auditing
Ligand’s reported revenue, Mr. Fazio failed to evaluate these factors
with the due care and professional skepticism required under the circumstances.
He also failed to identify and appropriately address issues concerning Ligand’s
policy of excluding certain types of returns from its estimates of future returns
and the adequacy of Ligand’s disclosure of this accounting policy.
In the Deloitte order, the Board found that, before Deloitte issued its audit
report, the firm's management was aware of facts and circumstances that raised
questions about Mr. Fazio's ability to lead public company audit engagements.
The PCAOB concluded by announcing that:
"Certain members of Deloitte’s management concluded first that Mr.
Fazio should be removed from public company audits and ultimately that he should
be asked to resign from the firm. Yet the firm left Mr. Fazio in place as the
engagement partner and did not take meaningful steps to assure the quality of
the audit work before issuing its audit report."
More than a year after the 2003 Ligand audit, Ligand announced that it would
restate its financial statements for 2003 and other periods, because its recognition
of revenue from product sales upon shipment was not in accordance with GAAP.
In its restatement, Ligand recognized approximately $59 million less in revenues
from product sales than originally reported (a decrease of approximately 52%)
and reported a net loss more than 2.5 times the net loss originally recognized
in that year.